Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781906 | 0.89 | ERN1 (0.62) | PTGS2PTGS1ERN1 | |
| SCHEMBL6781440 | 0.86 | CA1 (0.46) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL6780867 | 0.83 | ERN1 (0.58) | ERN1 | |
| SCHEMBL6536370 | 0.81 | ERN1 (0.51) | ERN1 | |
| SCHEMBL6782470 | 0.81 | ERN1 (0.62) | ERN1 | |
| SCHEMBL6536181 | 0.81 | ERN1 (0.63) | ERN1 | |
| SCHEMBL6781758 | 0.81 | IDO1 (0.45) | ERN1RAF1BRAF | |
| SCHEMBL6776941 | 0.80 | ERN1 (0.43) | ERN1 | |
| SCHEMBL6781727 | 0.80 | ERN1 (0.61) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL6536238 | 0.80 | MMP9 (0.44) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709646-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | PTGS2 680/4885PTGS1 629/4885CA12 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.